Expanded Access for CC-10004
- Conditions
- Bechet's Disease
- Registration Number
- NCT03740516
- Lead Sponsor
- Amgen
- Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does CC-10004 target in Behcet's Disease pathogenesis?
How does CC-10004 compare to standard-of-care therapies for Behcet's Disease in clinical trials?
Are there specific biomarkers associated with CC-10004 response in Behcet's Disease patients?
What adverse events are reported with CC-10004 in expanded access programs for Behcet's Disease?
What are the related compounds or combination therapies being explored for Behcet's Disease alongside CC-10004 by Amgen?
Trial Locations
- Locations (1)
Celgene
🇺🇸Summit, New Jersey, United States
Celgene🇺🇸Summit, New Jersey, United States